Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 16

474P - Potassium inward rectifier channel subfamily J member 11 mRNA expression in glioma and its significance in predicting prognosis and chemotherapy sensitivity

Date

14 Sep 2024

Session

Poster session 16

Presenters

kaijia zhou

Citation

Annals of Oncology (2024) 35 (suppl_2): S406-S427. 10.1016/annonc/annonc1587

Authors

K. zhou

Author affiliations

  • Neurooncology Department, Clinical Oncology School of Fujian Medical University, 350014 - Fuzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 474P

Background

We investigated KCNJ11 expression in different glioma tissue subtypes and its use as a predictor of glioma prognosis and sensitivity to temozolomide chemotherapy and determined the value of performance evaluation indicators.

Methods

Data on sex, age, histopathological type, WHO grade, IDH mutation, 1p/19q deletion, survival time, and KCNJ11 mRNA were collected from 516 patients with glioma. Expression levels and other data and uni- and multivariate Cox regression analyses were used to determine prognostic factors for patients with glioma. Data obtained from 603 cases with different glioma subtypes in TCGA database, 284 cases in REMBRANDT, and 264 cases in the United States database of the National Center for Biotechnology Information were verified to correlate KCNJ11 mRNA expression levels with the relationship between different clinical features and overall survival.

Results

KCNJ11 mRNA expression in 516 patients with different glioma subtypes correlated with histopathological type, WHO grade, IDH mutation status, 1p/19q co-deletion status, MGMT methylation, and WHO molecular classification (both P<0.05). Median survival times in the high KCNJ11 mRNA expression group were longer than those in the low expression group (P<0.05). Multivariate Cox regression analysis showed that age, tumor recurrence, WHO classification, IDH mutation, 1p/19q co-deletion, postoperative chemotherapy, and KCNJ11 mRNA expression were independent influencing factors of overall patient survival time. In the TCGA dataset, median overall survival times in the high expression group were longer than those in the low expression group (P<0.05). In the REMBRANDT dataset, median overall survival times in the high expression group was longer than those in the low expression group (P<0.05). In the GSE1101 dataset, median overall survival times in the high expression group was longer than those in the low expression group (P<0.05).

Conclusions

KCNJ11 mRNA expression was related to the degree of tumor malignancy and was an independent factor affecting overall survival time, and overall survival times of patients with high KCNJ11 mRNA expression are longer than those of patients with low KCNJ11 mRNA expression.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

K. Zhou.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.